AzTrials
AzTrials

Intraoperative BleedingNCT07585201

Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries

A study of Intraoperative Bleeding and Functional Endoscopic Sinus Surgeries, run by Zagazig University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. Read more about this study

Who is it for?
Ages 21 to 60 years
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
66 participants
Where
1 siteEgypt
Study dates
1 Sep 2022to 1 Mar 2023
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Physical status: American Society of Anesthesiologists (ASA) I \& II.
  • Body Mass Index (BMI): 18.5-30 kg/m2.
  • Type of operation: elective bilateral FESS.
  • Type of anesthesia: general anesthesia.

Who cannot join

  • Patients with known history of allergy to study drugs.
  • Anticipated difficult intubation.
  • Advanced hepatic, renal or cardiovascular diseases.
  • Central nervous system disorder, metabolic disease, and electrolyte imbalance.
  • Coagulopathies or taking drugs affecting coagulation.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Zagazig university

    Zagazig, Sharqia Province, 44111

Other trials in Egypt

About this study

Official title: Impact of Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries

Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. It is necessary to maintain safe conditions for this surgery, and the major problem reported during FESS under general anesthesia (GA) is impaired visibility due to excessive amount of bleeding. This is particularly important for the successful surgery of the ethmoid and sphenoid sinuses because even minimum amount of bleeding might seriously impair the successful completion of the surgery, increase the operational risk, and increase surgery time which are major concerns for both anesthesiologist and ENT specialist.

Controlled hypotension is the commonly used technique to limit blood loss and improve visualization in the surgical field during FESS, various techniques have been adopted to achieve controlled hypotension, one of them is the use of pharmacological drugs in the form of volatile anesthetics, direct-acting vasodilators, autonomic ganglion-blockers, and α-adrenergic receptor blockers.

Read more

Alpha-2 (α-2) receptors are found in the peripheral and central nervous systems, platelets and many other organs including the liver, pancreas, kidney, and eye. Stimulation of the receptors in the brain and spinal cord inhibits neuronal firing causing hypotension, bradycardia, sedation, and analgesia. Alpha-2 (α-2) agonist drugs have sympatholytic, sedative, anesthetic, and analgesic sparing effects, as well as vasoconstrictive effects and thereby reduce intraoperative bleeding. Also, the use of α-2 agonists in the perioperative period has been associated with reduced anesthetic requirements, decreased heart rate and blood pressure.

Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist (selectivity ratio for α2: α1 is 1600:1). The sympatholytic effect of dexmedetomidine made it attractive to be used as a hypotensive drug during surgery because of decreasing heart rate (HR) and cardiac output (CO) without decreasing stroke volume unless the plasma concentrates reaches above 5.1 μg/mL. The cardiovascular effects of dexmedetomidine begin with initial hypertension following the administration of a loading dose, due to the activation of α 2B receptors located on vascular smooth muscle, with subsequent hypotension and bradycardia due to centrally mediated decrease in sympathetic tone. Dexmedetomidine also has sedative, amnesic, anxiolytic, hypnotic, and analgesic effects with minimal changes in respiratory variables. Furthermore, it reduces postoperative nausea, vomiting, and shivering. It also reduces delirium in patients after cardiac surgery.

Nitroglycerin is a directly acting vasodilator drug frequently used to produce controlled hypotension because it is easily titratable and having very rapid onset as well as rapid offset of action. However, the disadvantages of nitroglycerin are reflex tachycardia and venous congestion which leads to increased blood loss.

Aim of the work was improving surgical field quality and drug cost in patients undergoing Functional Endoscopic Sinus Surgeries by comparing between dexmedetomidine and nitroglycerin.

Read the detailed description

This study had been carried out in Anesthesia, Intensive Care and Pain management Department - Faculty of Medicine - Zagazig University Hospitals.

Sample size:

Assuming the average category scale was 73.33% vs 36.67% in group D vs group N, so the sample was 66 adult male and female undergoing FESS , 33 cases in each group (dexmedetomidine and nitroglycerin) using open EPI info with CI 95%, Power of test 80%.

Withdrawal criteria:

The patient has the right to withdraw from the study at any time without any negative consequences or harm on his/her medical treatment plan.

Randomization:

All Patients were randomly allocated into 2 equal groups. Patients were randomized using computer generated randomization table in a 1:1 ratio and allocated either in dexmedetomidine group (group D) or nitroglycerin group (group N).

Randomization assignments were kept in sealed envelopes until the day of surgery, and then they opened by the research anesthesiologist immediately prior to the operation.

Process:

  • All participating patients were interviewed preoperatively during their preoperative preparation. The goal and endpoints of the study were discussed. Understanding of the technique was reviewed and emphasized.
  • History was taken, clinical examination was done, and informed written consent was obtained.
  • Fasting before the operation (8 hours for solid meal and 2 hours for clear fluids).
  • IV line was inserted; midazolam (0.02-0.05 mg/kg) was given as a premedication, started IV fluids as ringer lactate (8-10 ml/kg).
  • 10 minutes before induction of anesthesia, full monitoring including noninvasive arterial blood pressure, electrocardiogram, pulse oximetry, and capnogram (after induction of anesthesia) were applied and basal readings were recorded.
  • Preoxygenation with 100% oxygen for 3 minutes before induction.

Group (D):

Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.

Induction:

  • Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).

Maintenance:

  • Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes.
  • IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Group (N)

Induction:

  • Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).

Maintenance:

  • Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
  • IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Both drugs (dexmedetomidine and nitroglycerin) were titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.

Operations for both groups were carried out by the same surgical team. All the patients, surgeons, and the attending anesthetist who was assigned to record the patients' parameters were blinded to the infused drugs. The randomization envelopes, the syringe pumps, and their code labels were prepared by an anesthetist independent in the study.

Recovery period:

Patients were recovered with neostigmine (0.05-0.08 mg/kg) and atropine, the standard analgesia (paracetamol) was started at a dose of (15 mg/kg) then patients were transferred to the post anesthesia care unit (PACU) for observation.

Measurements:

  • The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:-

Fromme and Boezaart scoring system:

Grade Assessment 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible Heart rate and MAP basal readings were recorded then at 15 minutes time interval intraoperative.

Emergence time defined as the interval between discontinuation of the anesthetics to response of eye opening to the verbal command.

Recovery time defined as the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward were recorded.

The postoperative sedation was assessed with Ramsay Sedation Score Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.

The cost of both drugs was recorded.

Data collection:

  • Patient characteristics: age, sex, BMI, and physical status of patients included in the study.
  • MAP, heart rate and assessment score of surgical field intraoperative.
  • Emergence and recovery time.
  • Sedation score.
  • Drug cost.
  • Side effects or complications.
Being tested
controlled hypotension using dexmedetomidine, controlled hypotension hypotension using nitroglycerin
Keywords
Dexamedomidine, Nitroglycerin, Controlled Hypotension, Functional Endoscopic Sinus Surgeries
Medical subject headings
Blood Loss, Surgical, Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • controlled hypotension using dexmedetomidineDrug

    Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.

    Induction:

    Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).

    Maintenance:

    Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h.

    Dexmedetomidine was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.

  • controlled hypotension hypotension using nitroglycerinDrug

    Induction:

    • Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).

    Maintenance:

    • Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
    • IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Nitorglycerin) was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
Study groups in NCT07585201
Study groupRoleWhat they receive
Group DActive comparatordexmedetomidine as controlled hypotensive drug
Receives: Drug: controlled hypotension using dexmedetomidine
Group NActive comparatorNitroglycerin as controlled hypotensive drug
Receives: Drug: controlled hypotension hypotension using nitroglycerin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The quality of the surgical field

    The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:

    0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible

    Measured: perioperative

  2. Drug cost

    estimate and compare the drug cost in both groups by Egyptian pounds

    Measured: perioperative

Secondary outcomes (5)
  1. Emergence time

    the interval between discontinuation of the anesthetics to response of eye opening to the verbal command

    Measured: perioperative

  2. Mean arterial pressure

    MAP basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation

    Measured: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes

  3. Heart rate

    Heart rate basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation

    Measured: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes , 120 minutes

  4. Recovery time

    the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward

    Measured: perioperative

  5. Complications

    Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.

    Measured: perioperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2026
  2. Study start1 Sep 2022
  3. Primary completion28 Feb 2023
  4. Study completion1 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
66 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07585201
Sponsor's protocol ID
ZU-IRB #9667
Status last verified
Apr 2026
First submitted
22 Apr 2026
Last updated
13 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in